IL304467A - Pharmaceutical compositions for the treatment of breast cancer and methods of using them - Google Patents
Pharmaceutical compositions for the treatment of breast cancer and methods of using themInfo
- Publication number
- IL304467A IL304467A IL304467A IL30446723A IL304467A IL 304467 A IL304467 A IL 304467A IL 304467 A IL304467 A IL 304467A IL 30446723 A IL30446723 A IL 30446723A IL 304467 A IL304467 A IL 304467A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- pharmaceutical compositions
- breast cancers
- treating breast
- treating
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/151,108 US20210228529A1 (en) | 2012-07-13 | 2021-01-15 | Pharmaceutical compositions for treating breast cancers and methods of uses thereof |
PCT/US2022/012631 WO2022155543A1 (en) | 2021-01-15 | 2022-01-14 | Pharmaceutical compositions for treating breast cancers and methods of uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IL304467A true IL304467A (en) | 2023-09-01 |
Family
ID=82448697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL304467A IL304467A (en) | 2021-01-15 | 2023-07-13 | Pharmaceutical compositions for the treatment of breast cancer and methods of using them |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP4277613A1 (ja) |
JP (1) | JP2024503718A (ja) |
KR (1) | KR20230163362A (ja) |
CN (1) | CN116981451A (ja) |
AU (1) | AU2022208712A1 (ja) |
BR (1) | BR112023014247A2 (ja) |
CA (1) | CA3205212A1 (ja) |
IL (1) | IL304467A (ja) |
MX (1) | MX2023008375A (ja) |
WO (1) | WO2022155543A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115369089A (zh) * | 2022-08-11 | 2022-11-22 | 中山大学孙逸仙纪念医院 | 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途 |
CN117257994B (zh) * | 2023-11-21 | 2024-03-01 | 北京大学人民医院 | 动物模型的构建方法及应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2453981T3 (es) * | 2005-08-31 | 2014-04-09 | University Of Tennessee Research Foundation | Tratamiento de síntomas de enfermedad renal con moduladores selectivos de receptor de andrógenos (SARM) |
US10987334B2 (en) * | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
EP3474841B1 (en) * | 2016-06-22 | 2022-03-16 | Ellipses Pharma Ltd | Ar+ breast cancer treatment methods |
-
2022
- 2022-01-14 BR BR112023014247A patent/BR112023014247A2/pt unknown
- 2022-01-14 CN CN202280021307.2A patent/CN116981451A/zh active Pending
- 2022-01-14 KR KR1020237027185A patent/KR20230163362A/ko unknown
- 2022-01-14 MX MX2023008375A patent/MX2023008375A/es unknown
- 2022-01-14 JP JP2023543203A patent/JP2024503718A/ja active Pending
- 2022-01-14 WO PCT/US2022/012631 patent/WO2022155543A1/en active Application Filing
- 2022-01-14 AU AU2022208712A patent/AU2022208712A1/en active Pending
- 2022-01-14 EP EP22740195.7A patent/EP4277613A1/en active Pending
- 2022-01-14 CA CA3205212A patent/CA3205212A1/en active Pending
-
2023
- 2023-07-13 IL IL304467A patent/IL304467A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20230163362A (ko) | 2023-11-30 |
CA3205212A1 (en) | 2022-07-21 |
WO2022155543A1 (en) | 2022-07-21 |
BR112023014247A2 (pt) | 2023-10-03 |
JP2024503718A (ja) | 2024-01-26 |
AU2022208712A1 (en) | 2023-08-10 |
CN116981451A (zh) | 2023-10-31 |
EP4277613A1 (en) | 2023-11-22 |
MX2023008375A (es) | 2023-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL300067A (en) | Preparations and methods for the treatment of cancers | |
IL304467A (en) | Pharmaceutical compositions for the treatment of breast cancer and methods of using them | |
EP4034138A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS | |
IL268814A (en) | Preparations and methods for the treatment of cancer | |
IL285917A (en) | A pharmaceutical preparation that combines an immunological and chemotherapy method to treat cancer | |
EP4171606A4 (en) | COMPOSITIONS AND METHODS FOR TREATING COVID-19 | |
IL276203A (en) | Compounds and methods for treating cancer | |
IL289251A (en) | Methods and preparations for the treatment of pancreatic cancer | |
IL288787A (en) | Methods and preparations to improve results in cancer patients | |
IL309662A (en) | Compositions and methods for treating cancer | |
IL312844A (en) | Methods and preparations for the treatment of cancer | |
IL312846A (en) | Methods and preparations for the treatment of cancer | |
IL287538A (en) | Preparations and methods for the treatment of cancer | |
GB202018015D0 (en) | Composition and methods for the treatment of intestinal cancer | |
IL308766A (en) | Compositions and methods for treating prostate cancer | |
EP4149508A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | |
EP4114864A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CANCER | |
EP4111202A4 (en) | METHODS OF TREATING CANCER | |
GB202215066D0 (en) | Bifidobacterium and compositions thereof for breast cancer treatment | |
IL304591A (en) | Preparations and methods for the treatment of skin cancers | |
IL299039A (en) | Methods and preparations for the treatment of triple-negative breast cancer | |
IL311698A (en) | Cancer treatment methods and preparations and medicines for this | |
EP4237094A4 (en) | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE FOR THE TREATMENT OF CANCER | |
IL308642A (en) | Diagnostic methods and compositions for the treatment of cancer | |
IL312037A (en) | Endoxifen for the treatment of cancer |